A new collaboration targeting rare heart diseases has been formed between California’s BioMarin Pharmaceutical (Nasdaq: BMRN) and Swiss gene therapy firm DiNAQOR.
The pre-clinical research program will focus on novel gene therapies to treat rare genetic cardiomyopathies, with an undisclosed upfront payment for DiNAQOR, plus milestones and royalties.
The license initially covers the firm’s lead program, DiNA-001 for MYBPC3 hypertrophic cardiomyopathy (HCM).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze